Condition

Advanced Breast Cancer clinical trials and research

• 65Clinical trials
• 14NIH research projects
• 44Countries

Newest Advanced Breast Cancer clinical trials

All recruiting trials (65)

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• Timing ctDNA Testing to Guide Treatment in Advanced Breast Cancer

  This study tests how ctDNA levels and key gene mutations relate to outcomes and treatment responses in adults with advanced breast cancer.

  Recruiting Geneplus-Beijing Co. Ltd. · Beijing · NCT07681323

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• Metronomic Oral Paclitaxel for Advanced HER2-Negative Breast Cancer

  This study tests whether low, regular doses of an oral paclitaxel solution can be safely used to control tumor growth in adults with advanced HER2-negative breast cancer who have already had prior cancer therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07602907

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

• SYS6023 in combination with KN026 or HB1901 for advanced breast cancer

  This phase II study tests SYS6023 plus another agent to see if it is safe and may help people with unresectable or metastatic breast cancer.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Harbin, Heilonjiang · NCT07597629

• AK146D1 plus AK112 in advanced breast cancer

  This phase II study tests AK146D1 with AK112 to see if they are safe and can help shrink or control tumors in adults with advanced, HER2-negative breast cancer.

  Recruiting Phase 2 Akeso · Shanghai, Shanghai Municipality · NCT07591090

• Toripalimab plus doctor‑chosen chemotherapy for advanced HER2‑negative breast cancer

  This trial will test whether adding the PD‑1 drug toripalimab to a chemotherapy regimen chosen by your doctor helps people with recurrent or metastatic HER2‑negative breast cancer who have already had prior systemic therapy.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07540533

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• Camizestrant plus atirmociclib in ER-positive, HER2-negative advanced breast cancer

  This study tests whether combining camizestrant with atirmociclib is safe and tolerable in women whose ER-positive, HER2-negative advanced breast cancer progressed after a CDK4/6 inhibitor.

  Recruiting at 6 sites Phase 2 AstraZeneca · St Louis, Missouri and 5 other locations · NCT07427394

• Personalized diet to help women with advanced gynecologic or breast cancer on ADC therapy

  This study tests a personalized dietary plan versus general Mediterranean diet guidance in women with advanced gynecologic or breast cancer who are being treated with antibody-drug conjugates to see if nutrition can improve quality of life.

  Recruiting Phase 2 TNC Nutrición Terapéutica S.L. · Madrid, Madrid · NCT07406789

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• New oral medicine PF-08032562 for advanced or metastatic breast and colorectal cancer

  This trial will try an oral medicine called PF-08032562, given alone or with other cancer drugs, in adults with advanced or metastatic breast or colorectal cancer.

  Recruiting at 13 sites Phase 1 Pfizer · Duarte, California and 16 other locations · NCT07318805

• Ovarian suppression after ZOLADEX 10.8 mg in premenopausal women with HR+ breast cancer

  This study tests how well ZOLADEX 10.8 mg can suppress ovaries in premenopausal women with HR+ breast cancer.

  Recruiting at 26 sites Phase 1 TerSera Therapeutics LLC · Hot Springs, Arkansas and 25 other locations · NCT07310420

• Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment

  This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.

  Recruiting at 15 sites Phase 3 Women's Cancer Study Group GmbH · Anderlecht and 15 other locations · NCT07281833

• Finding better ways to detect resistance to antibody‑drug conjugates in solid tumors and identify useful biomarkers

  This trial tests whether tissue and blood biomarkers collected before and after treatment can reveal why antibody‑drug conjugates stop working in adults with advanced breast, gastric, urothelial, or non‑small cell lung cancer.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07259226

• TheraBionic P1 device in advanced HR-positive, HER2-negative breast cancer

  This trial tests whether the TheraBionic P1 device can help women with advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed on standard therapies, by looking at survival and disease control.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 7 other locations · NCT07227831

• Trastuzumab deruxtecan for adults with advanced breast cancer

  This trial tests trastuzumab deruxtecan in adults with advanced breast cancer to see if it is safe and works well.

  Recruiting RenJi Hospital · Shanghai · NCT07180264

• Iparomlimab and Tuvonralimab (QL1706) with CDK4/6 inhibitor and fulvestrant for HR-positive, HER2-negative advanced breast cancer

  This trial will test whether adding Iparomlimab and Tuvonralimab (QL1706) to a CDK4/6 inhibitor and fulvestrant helps women with hormone receptor–positive, HER2–negative advanced breast cancer get better tumor control or live longer.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07180160

• Continuous versus intermittent pyrotinib for HER2-positive advanced breast cancer

  This tests whether taking pyrotinib continuously or on an intermittent schedule works better and is safer for adults with HER2-positive advanced breast cancer.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07180082

• MHB036C combined with MHB039A for advanced breast cancer and other advanced solid tumors

  This trial will test whether the injectable combination of MHB036C and MHB039A is safe, well tolerated, and can shrink or control tumors in adults with advanced breast cancer or other advanced solid tumors.

  Recruiting Phase 2 Minghui Pharmaceutical (Hangzhou) Ltd · Shanghai, Shanghai Municipality · NCT07130383

• Shr2554 plus endocrine therapy in advanced breast cancer

  This study tests whether an all-oral SHR2554 combined with HRS-8080 can be safe and show preliminary activity in adults with advanced breast cancer.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07125950

• DM5167 for advanced breast cancer and other advanced solid tumors

  This Phase 1 trial will try DM5167, a PARP‑1 selective medicine, in adults with advanced breast cancer or other advanced solid tumors (with BRCA1/2 mutations) to see if it is safe and better tolerated than older PARP inhibitors.

  Recruiting at 4 sites Phase 1 Digmbio · Gyeonggi-do and 3 other locations · NCT07101601

• Trastuzumab rezetecan followed by CDK4/6 inhibitor plus hormone therapy for HR+/HER2‑low/ultra‑low advanced breast cancer

  This trial will test whether starting with trastuzumab rezetecan and then switching to a CDK4/6 inhibitor plus endocrine therapy helps women with HR-positive, HER2-low or ultra-low advanced breast cancer live longer without disease progression.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07037199

• BMS-986500 alone or with other therapies for advanced solid tumors

  This trial will test whether BMS-986500 by itself or combined with palbociclib and fulvestrant can help adults with advanced solid tumors, including breast and ovarian cancers, especially after CDK4/6 inhibitor treatment.

  Recruiting at 18 sites Phase 1 Bristol-Myers Squibb · Birmingham, Alabama and 20 other locations · NCT06997029

• ETX-636 treatment for advanced PIK3CA-mutant solid tumors and HR+ HER2- breast cancer

  This will test ETX-636 alone and together with fulvestrant in people with advanced solid tumors that have a PIK3CA mutation, including HR+, HER2- breast cancer.

  Recruiting at 15 sites Phase 1/2 Ensem Therapeutics · Newport Beach, California and 14 other locations · NCT06993844

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

• Assessing the effects of immunotherapy combined with radiotherapy in advanced breast cancer

  This study is testing if combining immunotherapy with radiotherapy can help people with advanced breast cancer feel better and improve their treatment results.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06776861

• HS-10502 combination treatment for advanced solid tumors

  This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06769425

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Testing MEN2312 in adults with advanced breast cancer

  This study is testing a new drug called MEN2312 to see if it can help adults with advanced breast cancer that can't be cured, after they have already tried other treatments.

  Recruiting at 45 sites Phase 1 Stemline Therapeutics, Inc. · Springdale, Arkansas and 44 other locations · NCT06638307

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Treatment for advanced breast cancer using RYZ101

  This study is testing a new treatment called RYZ101 for people with advanced breast cancer that can't be removed by surgery to see if it helps manage their condition.

  Recruiting Phase 1/2 RayzeBio, Inc. · Phoenix, Arizona and 30 other locations · NCT06590857

• Psychosocial intervention for managing symptoms in advanced cancer patients

  This study is testing a new telehealth program called ENGAGE to see if it can help people with advanced cancer manage their symptoms and improve their quality of life.

  Recruiting Duke University · Durham, North Carolina · NCT06555588

• Observing treatment outcomes for Chinese patients with advanced breast cancer and ESR1 mutations

  This study looks at how well different treatments work for Chinese patients with advanced breast cancer and specific gene mutations who haven't had success with previous hormone therapy.

  Recruiting SciClone Pharmaceuticals · Suzhou, Jiangsu · NCT06548919

• Understanding the in-home hospice experience for breast cancer patients

  This study looks at how to improve hospice care for breast cancer patients at home by checking in with them and their caregivers through telehealth to see what works best.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06507930

• Trastuzumab deruxtecan versus CDK4/6 inhibitor plus hormone therapy as first-line treatment for HR-positive, HER2-low non-luminal advanced breast cancer.

  This trial will see if trastuzumab deruxtecan (T-DXd) works better than a CDK4/6 inhibitor plus endocrine (hormone) therapy as first-line treatment for adults with HR-positive, HER2-low advanced breast cancer that is classified as non-luminal by gene profiling.

  Recruiting at 79 sites Phase 2 MedSIR · Graz and 78 other locations · NCT06486883

• ADCs plus adebrelimab in HER2-negative advanced breast cancer

  This study tests three antibody-drug conjugates (SHR-A1811, SHR-A1921, SHR-A2102) combined with adebrelimab to see if they help people with HER2-negative advanced breast cancer who have already tried other drugs.

  Recruiting Phase 2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06433609

• Combination treatment for advanced ER-positive breast cancer with ESR1 mutations

  This study is testing if a new combination of two drugs can help people with advanced ER-positive breast cancer that has specific mutations live longer and keep their cancer under control.

  Recruiting at 81 sites Phase 3 MedSIR · Innsbruck and 103 other locations · NCT06382948

• Combination of saruparib and camizestrant for advanced breast cancer treatment

  This study is testing if a new combination of two drugs, saruparib and camizestrant, can help people with advanced breast cancer who have certain genetic mutations feel better compared to the usual treatment.

  Recruiting at 242 sites Phase 3 AstraZeneca · Gilbert, Arizona and 305 other locations · NCT06380751

• Dalpiciclib for HR-positive, HER2-negative advanced breast cancer

  This study tests whether dalpiciclib is safe and helps people with hormone receptor–positive, HER2‑negative advanced breast cancer.

  Recruiting RenJi Hospital · Shanghai · NCT06301438

• Exploring HER3-DXd treatment for advanced breast cancer

  This study is testing a new treatment called HER3-DXd, both alone and with another drug, to see if it can help people with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France · NCT06298084

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

• Selecting Advanced Breast Cancer Patients for Talazoparib Treatment Using the RECAP Test

  This study is testing if a new test can help find advanced breast cancer patients who will benefit from a specific treatment called talazoparib.

  Recruiting at 3 sites Phase 2 Erasmus Medical Center · Leiden, South Holland and 2 other locations · NCT06193525

• Comparing two treatment approaches for advanced breast cancer

  This study is testing which treatment works better for people with advanced breast cancer that has low hormone receptor expression and is HER2-negative: a combination of chemotherapy and maintenance therapy or a CDK4/6 inhibitor with hormone therapy.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06176534

• Effects of fasting and exercise on fatigue in women with advanced breast cancer

  This study is testing whether fasting, exercise, a mix of both, or health education can help reduce fatigue in postmenopausal women with advanced breast cancer who are starting hormone therapy.

  Recruiting at 2 sites University of Miami · Phoenix, Arizona and 2 other locations · NCT06123988

• BGB-43395 treatment for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.

  Recruiting at 57 sites Phase 1 BeOne Medicines · Denver, Colorado and 60 other locations · NCT06120283

• Personalized treatment for advanced HER2-negative breast cancer using organoids

  This study is testing whether using personalized treatment based on lab-grown samples of a patient's tumor can help people with advanced HER2-negative breast cancer feel better compared to standard treatment chosen by their doctor.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT06102824

• Optimizing CDK 4/6-inhibitor doses for older breast cancer patients

  This study is testing if personalizing the dose of a breast cancer medication for older patients can help them get better results than just lowering the dose based on standard practices.

  Recruiting at 2 sites Phase 3 Region Örebro County · Helsinki and 11 other locations · NCT06044623

• Combining Everolimus with standard therapy for advanced breast cancer

  This study is testing if adding Everolimus to standard hormone therapy can help people with advanced breast cancer feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05949541

• Genetically-informed therapy for advanced ER+ breast cancer after CDK4/6 inhibitors

  This study is testing different drug combinations to see if they can help post-menopausal women with advanced ER+/HER2- breast cancer who have already been treated with certain medications.

  Recruiting Phase 2 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT05933395

• Using capecitabine and cyclophosphamide for advanced breast cancer maintenance therapy

  This study is testing if a combination of two drugs, capecitabine and cyclophosphamide, can help women with advanced breast cancer stay stable after their previous treatment.

  Recruiting RenJi Hospital · Shanghai · NCT05876065

• Treatment for HER2-low advanced breast cancer using Disitamab vedotin

  This study is testing a new treatment called Disitamab vedotin for people with HER2-low advanced breast cancer who have already tried one round of chemotherapy to see if it can help them feel better and live longer.

  Recruiting RenJi Hospital · Shanghai · NCT05831878

• Precision therapy for advanced breast cancer patients

  This study is testing different targeted treatments for patients with advanced breast cancer who have already tried certain medications, to see if personalized options can help them feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05594095

• Combining Fulvestrant with DNA Damage Repair Inhibitors for Advanced Breast Cancer

  This study is testing if combining Fulvestrant with DNA damage repair drugs can help people with advanced hormone receptor-positive breast cancer who haven't responded to previous treatments.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT05536128

• Combining Eribulin and a Trastuzumab-biosimilar for Advanced HER2-positive Breast Cancer

  This study is testing if combining two cancer drugs, eribulin and a trastuzumab-biosimilar, can help people with advanced HER2-positive breast cancer who have already tried other treatments.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT05530057

• Testing a new drug for advanced solid tumors and breast cancer with specific mutations

  This study is testing a new drug called RLY-2608 to see if it can help people with advanced solid tumors and breast cancer that have specific mutations.

  Recruiting at 36 sites Phase 1 Relay Therapeutics, Inc. · Tucson, Arizona and 36 other locations · NCT05216432

• Using tumor infiltrating lymphocytes to treat advanced breast cancer

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced breast cancer who haven't had success with other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT05142475

• Patritumab deruxtecan for unresectable or metastatic hormone-receptor–positive, HER2-negative breast cancer

  This trial will try patritumab deruxtecan (U3-1402) every three weeks in adults with HER2-negative, hormone-receptor–positive advanced or metastatic breast cancer whose disease progressed after endocrine therapy plus CDK4/6 inhibitors.

  Recruiting at 10 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 10 other locations · NCT04965766

• Using Talazoparib for Advanced Breast Cancer with Homologous Recombinant Deficiency

  This study is testing if a new drug called Talazoparib can help people with advanced breast cancer who have specific genetic mutations that affect their DNA repair.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT04892693

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like breast or prostate cancer, to see how safe it is and how well it works on its own or with other treatments.

  Recruiting at 11 sites Phase 2 Pfizer · Los Angeles, California and 38 other locations · NCT04557449

• New drug metarrestin for treating metastatic solid tumors

  This study is testing a new drug called metarrestin to see if it can safely shrink tumors in adults and teens with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 National Institutes of Health Clinical Center (CC) · Fairway, Kansas and 1 other locations · NCT04222413

• Registry for patients with advanced metastatic breast cancer in Southeast Netherlands

  This study is gathering information from patients with advanced breast cancer in Southeast Netherlands to see how different treatments are working in real life.

  Recruiting Academisch Ziekenhuis Maastricht · Maastricht · NCT03577197

NIH-funded research (14)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Radiomic markers from 3D mammography to predict breast cancer risk across diverse women

  A Mayo Clinic team is testing advanced computer-derived features from 3D mammograms to improve predicting who will develop breast cancer, including diverse groups of women.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11386848

• Improving how the immune system fights advanced breast cancer by relieving tumor pressure

  A breast cancer treatment study tests whether a common blood pressure drug (losartan) can help immune cells get into tumors and work better with immunotherapy.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11379056

• Using a blood test that looks for tumor DNA to monitor early and locally advanced breast cancer

  This project uses a sensitive blood test that looks for tiny bits of tumor DNA to track treatment response in people with early or locally advanced breast cancer.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11306078

• Personalizing estrogen therapy for ER-positive breast cancer

  This project finds how the hormone estrogen can kill certain ER-positive breast cancers and how to tell which patients will benefit.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11304574

• Longer overnight fasting and exercise to reduce fatigue in women with hormone receptor–positive advanced breast cancer

  This project will see if longer overnight fasting and regular exercise help women with hormone receptor–positive advanced breast cancer feel less fatigued and improve their quality of life.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11176126

• FFNP-PET scans to predict hormone therapy response in advanced ER-positive breast cancer

  This project uses a special PET scan called FFNP to find which people with ER-positive, HER2-negative advanced breast cancer are likely to benefit from hormone (endocrine) therapies.

  NIH research Washington University · Saint Louis, United States · NIH-11172663

• Monitoring breast cancer treatment using blood tests for tumor DNA

  This study is looking at how to better treat people with early and locally advanced breast cancer by checking for tiny bits of cancer DNA in their blood, which could help doctors spot any remaining cancer sooner and tailor treatments to each patient, reducing the chance of unnecessary therapies.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11136406

• Boosting the body's defenses against advanced breast cancer by easing tumor pressure

  This project explores how a common blood pressure medicine might help immune cells better fight advanced breast cancer.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11089375

• Investigating how a specific RNA affects the survival of advanced breast cancer cells

  This study is looking at a special molecule called MANCR that helps aggressive breast cancer cells survive, and by understanding how it works, the researchers hope to find new ways to treat patients with advanced breast cancer that doesn't respond to regular treatments.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11074071

• Understanding how estrogen therapy works for advanced breast cancer

  This study is looking into why some advanced breast cancers that have estrogen receptors respond well to estrogen therapy while others don’t, with the goal of finding better, personalized treatment options for patients based on their specific tumor traits.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11059927

• Effects of fasting and exercise on fatigue in women with advanced breast cancer

  This study is looking at how skipping breakfast and exercising might help women with advanced breast cancer feel less tired and improve their quality of life, especially for those from diverse backgrounds facing unique challenges.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10932148

• Using PET imaging to predict response to hormone therapy in advanced breast cancer

  This study is looking at a special type of imaging to see how well women with advanced estrogen receptor-positive breast cancer respond to hormone treatments, helping doctors figure out which patients might benefit the most from these therapies.

  NIH research Washington University · Saint Louis, United States · NIH-10914107

• Investigating factors that affect blood tests for early breast cancer detection

  This study is looking at how different ways of collecting and processing blood samples can help improve blood tests that check for early signs of breast cancer, and it's for patients with early or locally advanced breast cancer.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-10691211

• Examining lymph node biopsy techniques after chemotherapy in advanced breast cancer patients

  This study is looking at whether a less invasive procedure called sentinel lymph node biopsy can help women with locally advanced breast cancer who have received chemotherapy, making it easier to check for cancer spread in the armpit without needing more complicated surgeries.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10656553

Related topics

Quick answers

How many Advanced Breast Cancer clinical trials are recruiting right now?

65, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 44 countries. The most sites are in China (29 trials), United States (23 trials), France (11 trials), Spain (10 trials), South Korea (10 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 27, Phase 1: 12, Phase 3: 6, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →